What are the functions and effects of pemetinib? What types of cancer is it suitable for?

Pemigatinib is an oral targeted drug that is a tyrosine kinase inhibitor (TKI). It is primarily used to treat tumors driven by mutations or rearrangements of fibroblast growth factor receptor 2 (FGFR2). The mechanism of action of pemetinib is to interfere with the growth and spread of tumor cells by inhibiting the FGFR signaling pathway. FGFR is an important receptor involved in cell proliferation, differentiation and migration. Especially in certain types of cancer, abnormal activation of the FGFR pathway is closely related to the occurrence and development of tumors. By inhibiting this pathway, pemetinib can effectively slow or prevent tumor progression.

Pemetinib has shown promising results in the treatment of multiple tumor types, especially in cholangiocarcinoma, urothelial carcinoma, and some other FGFR mutation-driven tumors. Pemetinib has shown significant efficacy in cholangiocarcinoma, particularly in patients with FGFR2 fusions or rearrangements. These patients often respond poorly to traditional treatments such as chemotherapy and radiation, and pemetinib provides them with a new treatment option by targeting FGFR2 mutations.

In addition, pemetinib is also used to treat urothelial cancer, especially for patients with FGFR gene mutations or rearrangements. FGFRMutations are common in urothelial cancer. Pemetinib can effectively inhibit the proliferation of tumor cells and delay the progression of the disease.

Clinical studies have shown that pemetinib is not only effective in controlling these FGFR tumors driven by gene mutations, but is also generally well tolerated and has relatively controllable side effects. Common side effects include dry mouth, rash, hair loss, etc., but most of these side effects are mild and can be managed according to the guidance of the doctor during treatment.

In summary, pemetinib, as a targeted therapy drug, is mainly used to treat cancers driven by FGFR2 mutations or rearrangements, such as cholangiocarcinoma, urothelial cancer, etc. It has demonstrated significant efficacy and provides patients with new treatment options.